Table 3.

Adverse events (AEs) leading to treatment interruption, maximum concentration (C_max) and area under the curve from 0 to infinity (AUC_0–inf) of napabucasin on days 1 and 30 for each patient

Patient identifier for the study	Day 1 Cmax (ng/mL)	Day 30 Cmax (ng/mL)	Day 1 AUC0-inf (h ng/mL)	Day 30 AUC0-inf (h ng/mL)	Duration of treatment (days)	List of AEs related to treatment	AEs leading to treatment interruption
30,001	609	483	5249	4064	51	Anorexia Malaise Diarrhoea	N/A
30,002	381	464	3082	N/A	220	Diarrhoea Urine discolouration Diarrhoea Diarrhoea Diarrhoea Diarrhoea Diarrhoea Diarrhoea Diarrhoea Diarrhoea	Diarrhoea
30,003	720	N/A	3275	N/A	5	Diarrhoea Abdominal pain	Diarrhoea Abdominal pain
30,004	569	467	4073	N/A	338	Anorexia Diarrhoea Diarrhoea Malaise Diarrhoea Diarrhoea	Diarrhoea Malaise

N/A not applicable